利妥昔单抗对比硫唑嘌呤维持抗中性粒细胞胞质抗体相关性血管炎复发患者缓解的国际随机对照试验
RITAZAREM 试验在 7 国 29 中心纳入 188 例复发期 AAV 患者,先用利妥昔单抗和糖皮质激素再诱导缓解,4 个月内达缓解者随机接受利妥昔单抗(85 例)或硫唑嘌呤(85 例)维持治疗并随访至少 36 个月,利妥昔单抗预防复发优于硫唑嘌呤(HR 0.41,95%CI 0.27-0.61,p<0.001)。
要点
- 复发期 AAV 患者再诱导缓解后,利妥昔单抗固定间隔重复给药预防复发优于硫唑嘌呤(HR 0.41)。
- 利妥昔单抗组 19/85(22%)、硫唑嘌呤组 31/85(36%)在治疗期经历至少一次严重不良事件。
- 两组低丙种球蛋白血症或感染发生率无差异。
核心结论
- 在利妥昔单抗再诱导缓解后,固定间隔重复剂量利妥昔单抗在预防有复发史的 AAV 患者疾病复发方面优于硫唑嘌呤。
研究设计与样本
- RITAZAREM 为国际随机对照、开放标签、优效性试验,于 2013 年 4 月至 2016 年 11 月在 7 国 29 中心招募 188 例 AAV 复发时患者。
- 所有患者先接受利妥昔单抗和糖皮质激素再诱导缓解,4 个月内达缓解者随机接受利妥昔单抗静脉 1000 mg 每 4 个月至第 20 个月(85 例)或硫唑嘌呤 2 mg/kg/天、第 24 个月后逐渐减量(85 例),随访至少 36 个月。
- 主要结局为至疾病复发时间(主要或次要复发)。
主要发现
- 利妥昔单抗预防复发优于硫唑嘌呤:HR 0.41,95%CI 0.27 至 0.61,p<0.001。
- 治疗期间至少一次严重不良事件:利妥昔单抗组 19/85(22%)vs 硫唑嘌呤组 31/85(36%)。
- 两组低丙种球蛋白血症或感染发生率无差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Following induction of remission with rituximab in anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV) relapse rates are high, especially in patients with history of relapse. Relapses are associated with increased exposure to immunosuppressive medications, the accrual of damage and increased morbidity and mortality. The RITAZAREM trial compared the efficacy of repeat-dose rituximab to daily oral azathioprine for prevention of relapse in patients with relapsing AAV in whom remission was reinduced with rituximab. METHODS: RITAZAREM was an international randomised controlled, open-label, superiority trial that recruited 188 patients at the time of an AAV relapse from 29 centres in seven countries between April 2013 and November 2016. All patients received rituximab and glucocorticoids to reinduce remission. Patients achieving remission by 4 months were randomised to receive rituximab intravenously (1000 mg every 4 months, through month 20) (85 patients) or azathioprine (2 mg/kg/day, tapered after month 24) (85 patients) and followed for a minimum of 36 months. The primary outcome was time to disease relapse (either major or minor relapse). RESULTS: Rituximab was superior to azathioprine in preventing relapse: HR 0.41; 95% CI 0.27 to 0.61, p<0.001. 19/85 (22%) patients in the rituximab group and 31/85 (36%) in the azathioprine group experienced at least one serious adverse event during the treatment period. There were no differences in rates of hypogammaglobulinaemia or infection between groups. CONCLUSIONS: Following induction of remission with rituximab, fixed-interval, repeat-dose rituximab was superior to azathioprine for preventing disease relapse in patients with AAV with a prior history of relapse. TRIAL REGISTRATION NUMBER: NCT01697267; ClinicalTrials.gov identifier.
引用
- Smith RM, Jones RB, Specks U, et al. Rituximab versus azathioprine for maintenance of remission for patients with ANCA-associated vasculitis and relapsing disease: an international randomised controlled trial. Ann Rheum Dis. 2023. PMID: 36958796. doi:10.1136/ard-2022-223559
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。